2023-508435-31-00招募中1 期
First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Onkure Inc.
- 入组人数
- 82
- 试验地点
- 20
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Ann Howell
Scientific
Onkure Inc.
研究点 (20)
Loading locations...
相似试验
招募中
1 期
FIRST IN-HUMAN STUDY EVALUATING THE EFFECT OF VARIOUS DOSES OF ODM-212 IN SUBJECTS WITH SELECTED ADVANCED SOLID TUMOURSeoplasms benign malignant and unspecified (incl cysts and polyps). MedDRA [C04]MedDRA version: 20.0Level: SOCClassification code: 10029104Term: Neoplasms benign malignant and unspecified (incl cysts and polyps) Class: 2CTIS2022-503061-29-00Orion Corporation153
进行中（未招募）
1 期
First-in-human study evaluating the effect of various doses of ODM-212 in subjects with selected advanced solid tumourseoplasms, benign, malignant and unspecified (including cysts and polyps)CancerISRCTN99739590Orion Corporation (Finland)213
进行中（未招募）
1 期
A Phase I/II Study of HKI-272 in Combination With Vinorelbine in Subjects With Solid Tumors and Metastatic Breast Cancer. - HKI 2204Solid tumors (part 1) and metastatic breast cancer (part 2).MedDRA version: 9.1Level: LLTClassification code 10055113Term: Breast cancer metastaticEUCTR2007-007885-39-NLWyeth Research Division of Wyeth Pharmaceuticals Inc.95
进行中（未招募）
1 期
A Phase I/II Study of HKI-272 in Combination With Vinorelbine in Subjects With Solid Tumors and Metastatic Breast Cancer.EUCTR2007-007885-39-BEWyeth Research Division of Wyeth Pharmaceuticals Inc.95
进行中（未招募）
不适用
eratinib in combination with vinorelbine in metastatic breast cancer patientsEUCTR2007-007885-39-SEPuma Biotechnology, Inc95